Idiopathic Pulmonary Fibrosis
"Idiopathic Pulmonary Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.
| Descriptor ID |
D054990
|
| MeSH Number(s) |
C08.381.483.487.500 C08.381.765.500
|
| Concept/Terms |
Idiopathic Pulmonary Fibrosis- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibroses
- Pulmonary Fibroses, Idiopathic
- Familial Idiopathic Pulmonary Fibrosis
- Fibrocystic Pulmonary Dysplasia
- Dysplasia, Fibrocystic Pulmonary
- Dysplasias, Fibrocystic Pulmonary
- Fibrocystic Pulmonary Dysplasias
- Pulmonary Dysplasia, Fibrocystic
- Pulmonary Dysplasias, Fibrocystic
- Fibrosing Alveolitis, Cryptogenic
- Hamman-Rich Disease
- Disease, Hamman-Rich
- Diseases, Hamman-Rich
- Hamman Rich Disease
- Hamman-Rich Diseases
- Interstitial Pneumonitis, Usual
- Interstitial Pneumonitides, Usual
- Pneumonitides, Usual Interstitial
- Pneumonitis, Usual Interstitial
- Usual Interstitial Pneumonitides
- Usual Interstitial Pneumonitis
- Pulmonary Fibrosis, Idiopathic
- Usual Interstitial Pneumonia
- Interstitial Pneumonia, Usual
- Interstitial Pneumonias, Usual
- Usual Interstitial Pneumonias
- Idiopathic Fibrosing Alveolitis, Chronic Form
- Cryptogenic Fibrosing Alveolitis
- Cryptogenic Fibrosing Alveolitides
- Fibrosing Alveolitides, Cryptogenic
- Idiopathic Pulmonary Fibrosis, Familial
|
Below are MeSH descriptors whose meaning is more general than "Idiopathic Pulmonary Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Idiopathic Pulmonary Fibrosis".
This graph shows the total number of publications written about "Idiopathic Pulmonary Fibrosis" by people in this website by year, and whether "Idiopathic Pulmonary Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 3 | 0 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 5 | 0 | 5 |
| 2014 | 2 | 1 | 3 |
| 2015 | 9 | 0 | 9 |
| 2016 | 7 | 3 | 10 |
| 2017 | 3 | 2 | 5 |
| 2018 | 8 | 0 | 8 |
| 2019 | 12 | 2 | 14 |
| 2020 | 10 | 0 | 10 |
| 2021 | 12 | 0 | 12 |
| 2022 | 10 | 0 | 10 |
| 2023 | 15 | 0 | 15 |
| 2024 | 10 | 4 | 14 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Idiopathic Pulmonary Fibrosis" by people in Profiles.
-
Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation. Lancet Respir Med. 2025 Jun; 13(6):495-504.
-
Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Nat Commun. 2025 Apr 05; 16(1):3251.
-
mTOR signaling regulates multiple metabolic pathways in human lung fibroblasts after TGF-ß and in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2025 Feb 01; 328(2):L215-L228.
-
Single-Cell Analysis Reveals Novel Immune Perturbations in Fibrotic Hypersensitivity Pneumonitis. Am J Respir Crit Care Med. 2024 Nov 15; 210(10):1252-1266.
-
Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis. Am J Respir Crit Care Med. 2024 Sep 01; 210(5):639-647.
-
Machine Learning of Plasma Proteomics Classifies Diagnosis of Interstitial Lung Disease. Am J Respir Crit Care Med. 2024 Aug 15; 210(4):444-454.
-
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine. Am J Respir Crit Care Med. 2024 Aug 15; 210(4):401-423.
-
Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts. Am J Respir Crit Care Med. 2024 Aug 15; 210(4):455-464.
-
The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry. Respir Res. 2024 Jun 21; 25(1):255.
-
Machine learning classifier is associated with mortality in interstitial lung disease: a retrospective validation study leveraging registry data. BMC Pulm Med. 2024 May 23; 24(1):254.